A Study of Postural Tachycardia Syndrome

Overview

About this study

The purpose of this research study is to better understand what causes POTS. We believe that a number of different causes of POTS exist and that detailed testing can demonstrate the different causes. Knowing what causes POTS in a particular patient will be helpful in choosing the right treatment strategy for that particular patient in the future.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

POTS:

  • Males or females age 18-50 years.
  • Orthostatic HR increment of ≥30bpm to an absolute orthostatic HR ≥120bpm within 10 min of head-up tilt.
  • Frequent orthostatic symptoms (lightheadedness, faintness), that resolve promptly with recumbency

Control Subjects:

  • Males or females age 18-50 years, age and gender matched to patients
  • Normal Autonomic Reflex Screen, normal Autonomic Symptom Profile

Subjects Undergoing Skin Biopsy and Autonomic Reflex Screen Only

  • Males or females age 18-80 years

Exclusion Criteria

POTS and Controls

  • Orthostatic hypotension (decrease of systolic BP≥30mmHg and/or diastolic BP≥15mmHg within 3min of tilt)
  • Pregnant/lactating females – a pregnancy test will be required for women of childbearing potential.
  • The presence of failure of other organ systems or systemic illness that can affect autonomic function.
  • Concomitant therapy with anticholinergic, alpha-/beta-adrenergic antagonists or other medication which could interfere with autonomic testing. Potentially interfering medication will be held for five half-lives.

Subjects Only Undergoing Skin Biopsy and Autonomic Reflex Screen Only

  • Pregnant/lactating females – a pregnancy test will be required for women of childbearing potential.
  • The presence of failure of other organ systems or systemic illness that can affect autonomic function.
  • Concomitant therapy with anticholinergic, alpha-/beta-adrenergic antagonists or other medication which could interfere with autonomic testing. Potentially interfering medication will be held for five half-lives.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Wolfgang Singer, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer